ANCA vasculitis: what is in the pipeline

Area of Science:

• Immunology
• Rheumatology
• Internal Medicine

Background:

• Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is increasingly recognized as a complex immune-mediated inflammatory disorder.
• Recent advances in understanding ANCA specificity, complement activation, neutrophil extracellular trap formation, genetic susceptibility, and environmental triggers have reshaped disease concepts.

Purpose of the Study:

• To review recent developments in the understanding and treatment of AAV.
• To highlight how these advances are informing current treatment strategies, disease stratification, and drug development.

Main Methods:

• Focused review of recent scientific literature and clinical trial data.
• Analysis of emerging therapeutic targets and treatment modalities in AAV.

Main Results:

• Treatment has shifted from conventional therapies to targeted, steroid-sparing approaches, with rituximab being central.
• New therapies like avacopan, IL-5 blockade, next-generation anti-CD20 antibodies, CAR-T cell strategies, and complement-directed therapies are reducing glucocorticoid exposure and toxicity.
• Emerging treatments target B-cell pathways, including BAFF/APRIL blockade and tyrosine kinase inhibitors.

Conclusions:

• Improved biologic insights are enabling biomarker-driven classification and mechanism-based therapy selection in AAV.
• These advances aim to reduce treatment-related morbidity, enhance remission durability, and support personalized clinical care and research.